March 3, 2026

Genomic profiling of early-stage resectable non-small-cell lung cancer in a Malaysian private healthcare setting: Real-world clinical implications.

Key Points

Early-stage non-small-cell lung cancer reveals a high prevalence of EGFR mutations, especially in women and non-smokers.
Observational analysis shows significant relationships between EGFR mutations and tumor grade, with no link to PD-L1 expression.
Genomic profiling helps shape biomarker-driven treatment strategies for resectable non-small-cell lung cancer.
Reflex genomic testing poses potential for improved clinical outcomes with targeted therapies based on genetic insights.

Abstract

This is the first genomic molecular profiling study to report exclusively on early-stage NSCLC in Malaysia. The high prevalence of EGFR mutations observed, predominantly involved sensitizing mutations at exons 19 and 21, and was associated with the female sex, a non- smoking status, higher tumour grade, but not PD-L1 expression. Early reflex genomic testing is vital to guide biomarker-driven peri-operative treatment strategies for rNSCLC.

Genomic profiling of early-stage resectable non-small-cell lung cancer in a Malaysian private healthcare setting: Real-world clinical implications.

Key Points

Abstract

Cite This Study